Clinical Trials
48 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT06810141 2026-05-14
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
ImmunityBio, Inc.
Available
NCT06443944 2026-04-14
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
CG Oncology, Inc.
Available
NCT06877676 2026-04-13
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Janssen Research & Development, LLC
Approved for marketing
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT06836648 2026-02-25
Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT06090331 2025-07-08
89Zr-DFO-girentuximab Expanded Access Program (EAP)
Telix Pharmaceuticals (Innovations) Pty Limited
Available
NCT05401214 2025-06-13
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
Janssen Research & Development, LLC
Approved for marketing
NCT05650476 2025-06-12
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Pfizer
Available
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT05494411 2025-02-28
Named Patient Program for Mitomycin for Pyelocalyceal Solution
UroGen Pharma Ltd.
Available
NCT06033001 2025-01-13
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lantheus Medical Imaging
Temporarily not available
NCT05941637 2024-12-31
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Lynkcell Europe
No longer available
NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT05002465 2023-09-11
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer
University of Texas Southwestern Medical Center
No longer available
NCT05415228 2023-05-18
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
University of Michigan
No longer available
NCT04854369 2023-04-11
Firefly
Tulane University
No longer available
NCT04825652 2023-01-13
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Advanced Accelerator Applications
No longer available
NCT04452136 2022-03-14
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
OHSU Knight Cancer Institute
Approved for marketing
NCT03501940 2022-01-21
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Stanford University
No longer available
NCT04800068 2022-01-21
Expanded Access [Ga-68] PSMA-11 PET Imaging
Mayo Clinic
No longer available
NCT03801278 2021-12-13
FPA144
Five Prime Therapeutics, Inc.
No longer available
NCT04348682 2021-06-24
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging
Jonsson Comprehensive Cancer Center
Approved for marketing
NCT04337099 2021-05-05
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
Matrix Biomed, Inc.
Available
NCT04377152 2021-03-01
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
University of California, San Francisco
Approved for marketing
NCT02826395 2020-07-24
C11 Sodium Acetate PET/CT Imaging of PCa
Jonsson Comprehensive Cancer Center
No longer available
NCT02531672 2020-06-05
Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
Memorial Sloan Kettering Cancer Center
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT04136808 2020-01-13
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Astellas Pharma Inc
Approved for marketing
NCT03386071 2019-01-16
Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib
Jonsson Comprehensive Cancer Center
No longer available
NCT01834209 2018-11-07
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
No longer available
NCT01777061 2018-05-16
Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan
University of Kansas Medical Center
No longer available
NCT03005262 2018-04-04
MLN8237 for a Subject With Adenocarcinoma of the Prostate
The University of Texas Health Science Center at San Antonio
No longer available
NCT01217697 2017-03-24
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Approved for marketing
NCT01956253 2017-03-14
Single Subject Neratinib in Bladder Cancer (NRR)
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT02355054 2017-01-20
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Washington University School of Medicine
Approved for marketing
NCT02589717 2016-11-02
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Genentech, Inc.
Approved for marketing
NCT01516762 2014-07-14
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
No longer available
NCT01473043 2014-05-30
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
Pfizer
No longer available
NCT00130897 2012-03-09
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Pfizer
Approved for marketing
NCT00655252 2011-08-19
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
Novartis
No longer available
NCT00636259 2008-06-11
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
AstraZeneca
No longer available